vTv Therapeutics Inc.

Contributing Author

Recent Articles by vTv Therapeutics Inc.

7 hours	vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting VTVT GlobeNewswire
Sep-03	UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-03	vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-02	vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund VTVT GlobeNewswire
Aug-12	vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update VTVT GlobeNewswire
Aug-11	vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin VTVT GlobeNewswire
Aug-07	vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes VTVT GlobeNewswire
Jun-11	vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series VTVT GlobeNewswire
May-19	vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin VTVT GlobeNewswire
May-15	vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update VTVT GlobeNewswire
May-15	vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes VTVT GlobeNewswire